300584.SZ · 海辰药业
China A-shares · RS rating 13 · As of 2026-10-14
| Price | 29.69 CNY |
|---|---|
| 1-day change | -3.6% |
| RS rating (overall / 1M / 3M / 12M) | 13 / 58 / 31 / 6 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 29 / 16 / 17 |
| Industry group (rank) | Medical-Generic Drugs (40) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +27.1% |
| Distance from 52-week high | +58.7% |
| Market cap (USD) | $601.6M |